Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
70.65
-0.80 (-1.12%)
At close: Aug 26, 2026, 4:00 PM EDT
70.89
+0.24 (0.34%)
Pre-market: Aug 27, 2026, 8:17 AM EDT
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Tarsus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $94.86. The average 1-year stock price forecast is 34.27% higher than the current stock price, while the lowest is $84 (+18.90%) and the highest is $104 (+47.20%).
Price Target: $94.86 (+34.27%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 8 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 12, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $100 | Buy | Maintains | $100 | +41.54% | Aug 12, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $97 → $100 | Buy | Reiterates | $97 → $100 | +41.54% | Aug 12, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $104 | Buy | Reiterates | $104 | +47.20% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $88 | Buy | Reiterates | $88 | +24.56% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
713.62M
from 451.36M
Increased by 58.10%
Revenue Next Year
925.34M
from 713.62M
Increased by 29.67%
EPS This Year
-2.13
from -1.59
EPS Next Year
2.33
from -2.13
EPS and Forward PE are based on non-GAAP adjusted numbers.